keyword
https://read.qxmd.com/read/38726507/long-term-psychiatric-and-endocrine-complications-following-hematopoietic-stem-cell-transplantation-in-hematologic-disease-in-korea-a-nation-wide-cohort-study
#1
JOURNAL ARTICLE
Min Ji Jeon, Eunjin Noh, Seok Joo Moon, Eun Sang Yu, Chul Won Choi, Dae Sik Kim, Eun Joo Kang
PURPOSE: Numerous patients experience long-term complications after HSCT. This study aimed to identify the frequency and risk factors for psychiatric and endocrine complications following HSCT through big data analyses. MATERIALS AND METHODS: We established a cohort of patients with hematologic disease who underwent HSCT in Korea between 2010 and 2012 using the Health Insurance Review & Assessment Service data. A total of 3,636 patients were identified, and insurance claims were tracked using psychiatric and endocrine diagnostic International Classification of Diseases-10th Revision codes for the ensuing decade...
May 9, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38707796/impact-of-age-70-years-or-older-on-donors-for-living-donor-kidney-transplantation
#2
JOURNAL ARTICLE
Takahisa Hiramitsu, Tomoki Himeno, Yuki Hasegawa, Kenta Futamura, Manabu Okada, Yutaka Matsuoka, Norihiko Goto, Toshihiro Ichimori, Shunji Narumi, Asami Takeda, Takaaki Kobayashi, Kazuharu Uchida, Yoshihiko Watarai
INTRODUCTION: Kidney transplantation (KT) involving elderly living kidney donors (LKDs) is becoming more frequent because of a profound organ shortage. The efficacy of KT involving grafts obtained from LKDs aged 70 years or older has been reported. However, the safety of donor nephrectomy in LKDs aged 70 years or older, including that associated with changes in the estimated glomerular filtration rate (eGFR), has not been investigated. This study investigated the outcomes of LKDs aged 70 years or older after donor nephrectomy...
May 2024: KI Reports
https://read.qxmd.com/read/38703824/comparison-of-older-related-vs-younger-unrelated-donors-for-old-recipients-of-allogeneic-hematopoietic-cell-transplantation-with-aml-or-mds-a-large-single-center-analysis
#3
JOURNAL ARTICLE
Haesook T Kim, Vincent T Ho, Sarah Nikiforow, Corey Cutler, John Koreth, Roman M Shapiro, Mahasweta Gooptu, Rizwan Romee, Catherine J Wu, Joseph H Antin, Jerome Ritz, Robert J Soiffer
For patients undergoing allogeneic hematopoietic cell transplantation (alloHCT), HLA-matched related donors (MRDs) have traditionally been the preferred donor source. However, as the age of recipient increases, their sibling donors are likely aged as well. In this study, we investigated whether younger matched unrelated donors (MUDs) might be a better donor source than similarly aged siblings for patients over the age 60 years with AML or MDS. Four hundred ninety nine patients with AML or MDS age between 60 and 70 years who underwent alloHCT from an older MRD (donor age ≥50 years) or younger MUD (donor age ≤35 years) between 2010 and 2022 were evaluated...
May 3, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38701350/venetoclax-a-new-player-in-the-treatment-of-children-with-high-risk-myeloid-malignancies
#4
JOURNAL ARTICLE
Riccardo Masetti, Francesco Baccelli, Davide Leardini, Franco Locatelli
Venetoclax selectively inhibits BCL-2 and restores apoptotic signaling of hematological malignant cells. Venetoclax in combination with hypomethylating and low-dose cytotoxic agents has revolutionized the management of elderly patients affected by acute myeloid leukemia (AML), as well as that of patients unfit to receive intensive chemotherapy. In a single phase 1 pediatric trial conducted on relapsed/refractory AML, the combination of venetoclax with intensive chemotherapy was shown to be safe and yielded promising response rates...
May 3, 2024: Blood Advances
https://read.qxmd.com/read/38698745/umbilical-cord-blood-and-uc-mscs-combined-with-low-dose-immunosuppressant-in-the-treatment-of-elderly-patients-with-pure-red-cell-aplastic-a-case-series
#5
Wei-Wei Zhu, Sujing Zhuang, Zhe Yu, Xin Li, Tian-Jie Han, Yue Ma, Li-Jun Li, Zhi-Rui Zhao
INTRODUCTION: At present, cyclosporine (CsA) is the first-line treatment for Pure Red Cell Aplasia (PRCA), but CsA administration can be associated with a number of side effects due to its high toxicity. Therefore, it is urgent to explore a safe and effective treatment for elderly patients who cannot be treated with conventional doses of CsA, especially those with multiple complications. Allogeneic Stem Cell Transplantation (ASCT) for PRCA is a promising treatment, but reports of using umbilical cord blood (UCB) are very rare...
May 2, 2024: Current Stem Cell Research & Therapy
https://read.qxmd.com/read/38694393/richter-supraumbilical-hernia-managed-with-invagination-a-case-report
#6
Santosh Dev, Prajjwol Luitel, Sujan Paudel, Shishir Devkota, Laxman Khadka, Sanjeev Jha, Barsha Dev, Nischal Neupane, Bikal Ghimire
INTRODUCTION AND IMPORTANCE: Richter's hernia is an incarceration of the anti-mesenteric border of a segment of bowel through an abdominal wall defect. It primarily affects elderly individuals but can occur at any age, with a slightly increased incidence in females. The increase in laparoscopic and robotic-assisted procedures has led to a rise in Richter's hernias. CASE PRESENTATION: A 40-year-old male with a history of laparoscopic cholecystectomy and kidney transplantation presented with a 4-day history of supraumbilical swelling and abdominal pain...
May 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38686099/kidney-transplantation-improves-health-related-quality-of-life-in-older-recipients
#7
JOURNAL ARTICLE
Silke E de Boer, Tim J Knobbe, Daan Kremer, Barbara C van Munster, Gertrude J Nieuwenhuijs-Moeke, Robert A Pol, Stephan J L Bakker, Stefan P Berger, Jan Stephan F Sanders
Kidney transplantation is the best treatment for kidney failure in older patients. However, little is known regarding changes in health-related quality of life (HRQoL) from before to after transplantation and determinants of HRQoL in older kidney transplant recipients (KTR). We studied both, using data of older (≥65 years) patients waitlisted for kidney transplantation and older KTR 1 year after transplantation from the TransplantLines Biobank and Cohort Study. HRQoL was assessed using the SF-36 questionnaire...
2024: Transplant International
https://read.qxmd.com/read/38683145/the-cd33xcd123xcd70-multispecific-cd3-engaging-darpin-mp0533-induces-selective-t-cell-mediated-killing-of-aml-leukemic-stem-cells
#8
JOURNAL ARTICLE
Matteo Bianchi, Christian Reichen, Amelie Croset, Stefanie Fischer, Aline Eggenschwiler, Yvonne Grübler, Rajlakshmi Marpakwar, Thamar Looser, Patricia Spitzli, Christel Herzog, Denis Villemagne, Dieter Schiegg, Liridon Abduli, Chloé Iss, Alexandra Neculcea, Marco Franchini, Tamara Lekishvili, Simone Ragusa, Christof Zitt, Yvonne Kaufmann, Alienor Auge, Martin Hänggi, Waleed Ali, Teresa M Frasconi, Stephan Wullschleger, Iris Schlegel, Mirela Matzner, Ursina Lüthi, Bernd Schlereth, Keith M Dawson, Vladimir Kirkin, Adrian F Ochsenbein, Sebastian Grimm, Nina Reschke, Carsten Riether, Daniel Steiner, Nicolas Leupin, Anne Goubier
The prognosis of patients with acute myeloid leukemia (AML) is limited, especially for elderly or unfit patients not eligible for hematopoietic stem cell (HSC) transplantation. The disease is driven by leukemic stem cells (LSCs), which are characterized by clonal heterogeneity and resistance to conventional therapy. These cells are therefore believed to be a major cause of progression and relapse. We designed MP0533, a multispecific CD3-engaging DARPin (designed ankyrin repeat protein) that can simultaneously bind to three antigens on AML cells (CD33, CD123, and CD70), aiming to enable avidity-driven T cell-mediated killing of AML cells co-expressing at least two of the antigens...
April 29, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38673885/emerging-therapeutic-strategies-in-sarcopenia-an-updated-review-on-pathogenesis-and-treatment-advances
#9
REVIEW
Alfred Najm, Adelina-Gabriela Niculescu, Alexandru Mihai Grumezescu, Mircea Beuran
Sarcopenia is a prevalent degenerative skeletal muscle condition in the elderly population, posing a tremendous burden on diseased individuals and healthcare systems worldwide. Conventionally, sarcopenia is currently managed through nutritional interventions, physical therapy, and lifestyle modification, with no pharmaceutical agents being approved for specific use in this disease. As the pathogenesis of sarcopenia is still poorly understood and there is no treatment recognized as universally effective, recent research efforts have been directed at better comprehending this illness and diversifying treatment strategies...
April 12, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38670166/susceptibility-of-solid-organ-transplant-recipients-to-viral-pathogens-with-zoonotic-potential-a-mini-review
#10
REVIEW
Karine C Bezerra, Carlos Meton A G Vieira, Edmilson F de Oliveira-Filho, Christian Robson S Reis, Reinaldo B Oriá
A substantial number of zoonotic diseases are caused by viral pathogens, representing a significant menace to public health, particularly to susceptible populations, such as pregnant women, the elderly, and immunocompromised individuals. Individuals who have undergone solid organ transplantation frequently experience immunosuppression, to prevent organ rejection and, thus more prone to opportunistic infections. Furthermore, the reactivation of dormant viruses can threaten transplant recipients and organ viability...
April 23, 2024: Brazilian Journal of Infectious Diseases
https://read.qxmd.com/read/38665943/real-world-evidence-on-tagraxofusp-for-blastic-plasmacytoid-dendritic-cell-neoplasm-collected-cases-from-a-single-center-and-case-reports
#11
JOURNAL ARTICLE
Philipp Faustmann, Jan C Schroeder, Lucas Mix, Lennart Harland, Andreas Riedel, Wichard Vogel, Claudia Lengerke, Stefan Wirths
INTRODUCTION: Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is a rare, aggressive hematologic malignancy. Until recently, the only curative treatment consisted of intensive chemotherapy, followed by hematopoietic cell transplantation (HCT) in eligible adult cases. Tagraxofusp, a CD123-targeted protein-drug conjugate and the first approved targeted treatment for BPDCN, might enhance outcomes especially in patients not eligible for intensive therapies. METHODS: Here, we report real-world outcomes of five male patients with a median age of 79 years who received tagraxofusp as first-line treatment for BPDCN...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38642470/analysis-of-csf3r-mutations-in-atypical-chronic-myeloid-leukemia-and-other-myeloid-malignancies
#12
JOURNAL ARTICLE
Seon Young Kim, Ik-Chan Song, Jimyung Kim, Gye Cheol Kwon
We report a series of patients with CSF3R-mutant (CSF3Rmut ) atypical chronic myeloid leukemia (aCML), chronic neutrophilic leukemia (CNL) or other hematologic malignancies. We included 25 patients: 5 aCML and 4 CNL CSF3Rmut patients; 1 aCML, 2 CNL, and 2 myelodysplastic/myeloproliferative neoplasm, not otherwise specified patients without CSF3R mutation; and 11 CSF3Rmut patients with other diseases [8 acute myeloid leukemia (AML), 1 chronic myelomonocytic leukemia (CMML), 1 myelodysplastic syndrome (MDS), and 1 acute lymphoblastic leukemia (ALL)]...
April 18, 2024: Annals of Diagnostic Pathology
https://read.qxmd.com/read/38642272/the-role-of-the-gut-microbiome-in-health-and-disease-in-the-elderly
#13
REVIEW
Lea Ann Chen, Kaitlyn Boyle
PURPOSE OF REVIEW: Growing evidence supports the contribution of age in the composition and function of the gut microbiome, with specific findings associated with health in old age and longevity. RECENT FINDINGS: Current studies have associated certain microbiota, such as Butyricimonas, Akkermansia, and Odoribacter, with healthy aging and the ability to survive into extreme old age. Furthermore, emerging clinical and pre-clinical research have shown promising mechanisms for restoring a healthy microbiome in elderly populations through various interventions such as fecal microbiota transplant (FMT), dietary interventions, and exercise programs...
April 20, 2024: Current Gastroenterology Reports
https://read.qxmd.com/read/38632155/treatment-of-myelodysplastic-syndromes-for-older-patients-current-state-of-science-challenges-and-opportunities
#14
REVIEW
Tariq Kewan, Maximillian Stahl, Jan Philipp Bewersdorf, Amer M Zeidan
PURPOSE OF REVIEW: Myelodysplastic syndromes/neoplasms (MDS) represent a diverse group of pathologically distinct diseases with varying prognoses and risks of leukemia progression. This review aims to discuss current treatment options for elderly patients with MDS, focusing on patients ineligible for intensive chemotherapy or allogenic hematopoietic stem cell transplantation (HSCT). The challenges associated with treatment in this population and emerging therapeutic prospects are also explored...
April 18, 2024: Current Hematologic Malignancy Reports
https://read.qxmd.com/read/38616374/poor-nutritional-status-is-associated-with-death-in-a-population-of-dialyzed-older-persons
#15
JOURNAL ARTICLE
D Azzolino, S Vettoretti, M M Poggi, A Soldati, L Caldiroli, L A Dalla Vecchia, M Cesari
BACKGROUND: Older patients in hemodialysis have high prevalence of malnutrition that is often associated with rapid weight loss till cachexia. OBJECTIVES: We aimed to investigate whether in older patients undergoing hemodialysis the association between poor nutritional status and mortality may be independent of comorbidities and other risk factors. DESIGN: Retrospective longitudinal study. SETTING: Unit of Nephrology, Dialysis and Kidney Transplantation of the Policlinic Hospital of Milan, Milan, Italy...
2024: Journal of Frailty & Aging
https://read.qxmd.com/read/38613549/discussion-to-changes-in-heart-transplant-outcomes-of-elderly-patients-in-the-new-allocation-era
#16
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 11, 2024: Journal of Thoracic and Cardiovascular Surgery
https://read.qxmd.com/read/38610812/venetoclax-combination-treatment-of-acute-myeloid-leukemia-in-adolescents-and-young-adult-patients
#17
REVIEW
Elena Chatzikalil, Kleoniki Roka, Panagiotis T Diamantopoulos, Efthymia Rigatou, Georgia Avgerinou, Antonis Kattamis, Elena E Solomou
Over the past two decades, the prognosis in adolescents and young adults (AYAs) diagnosed with acute myeloid leukemia (AML) has significantly improved. The standard intensive cytotoxic treatment approach for AYAs with AML, consisting of induction chemotherapy with anthracycline/cytarabine combination followed by consolidation chemotherapy or stem cell transplantation, has lately been shifting toward novel targeted therapies, mostly in the fields of clinical trials. One of the most recent advances in treating AML is the combination of the B-cell lymphoma 2 (Bcl-2) inhibitor venetoclax with hypomethylating agents, which has been studied in elderly populations and was approved by the Food and Drug Administration (FDA) for patients over 75 years of age or patients excluded from intensive chemotherapy induction schemas due to comorbidities...
April 1, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38610618/transplant-candidates-of-70-years-have-superior-survival-if-receiving-pre-emptively-a-living-donor-kidney
#18
JOURNAL ARTICLE
Michiel G H Betjes, Marcia M L Kho, Joke Roodnat, Annelies E de Weerd
Background : The number of kidney transplant recipients over 70 years of age is increasing but detailed data on patient and graft survival in the modern era of immune suppression are few. Methods : A single-center cohort of patients of 70 years and older (n = 349) at time of kidney transplantation from 2010-2020 were followed until January 2023. Results : The median age was 73 years with a median follow-up of 4.3 years. Fifty percent of recipients of a living donor kidney (LDK, n = 143) received their graft pre-emptively...
March 23, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38607739/current-understanding-of-marginal-grafts-in-liver-transplantation
#19
REVIEW
Ze Xiang, Jiarui Li, Huixuan Zeng, Xiaonan Xiang, Fengqiang Gao, Kai Wang, Xuyong Wei, Shusen Zheng, Xiao Xu
End-stage liver disease (ESLD), stemming from a spectrum of chronic liver pathologies including chronic liver failure, acute cirrhosis decompensation and hepatocellular carcinoma, imposes a significant global healthcare burden. Liver transplantation (LT) remains the only treatment for ESLD. However, the escalating mortality on transplant waitlists has prompted the utilization of marginal liver grafts in LT procedures. These grafts primarily encompass elderly livers, steatotic livers, livers from donation after circulatory death, split livers and those infected with the hepatitis virus...
April 7, 2024: Aging and Disease
https://read.qxmd.com/read/38601118/mesenchymal-stem-cell-based-therapies-for-treating-well-studied-neurological-disorders-a-systematic-review
#20
Gaurav Deepak Patel, Lichao Liu, Ailian Li, Yun-Hsuan Yang, Chia-Chi Shen, Beate Brand-Saberi, Xuesong Yang
BACKGROUND: Millions of people across the globe are affected by conditions like Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI), and Traumatic Brain Injury (TBI), although most occurrences are common in the elderly population. This systematic review aims to highlight the safety of the procedures, their tolerability, and efficacy of the available therapies conducted over the years using mesenchymal stem cells (MSCs) in treating the neurological conditions mentioned above...
2024: Frontiers in Medicine
keyword
keyword
52210
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.